SILVER SPRING, Md.,
April 11, 2012 /PRNewswire/ --Sunpeaks Ventures, Inc.
(OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks
Ventures") and its wholly owned subsidiary Healthcare Distribution
Specialists, LLC ("HDS") are pleased to announce that HDS has
entered into an agreement with DS Healthcare Limited to assist in
introducing Clotamin to the UK/EU market.
Under terms of the agreement, DS Healthcare will evaluate the
Clotamin formulation and claims against the European Union Food
Supplement Directive, the Nutritional Health Claims Directive, and
Food Labeling Regulations to determine any specific actions and
timeline required to introduce Clotamin to the UK/EU market.
"The UK and European Union market represent an enormous
opportunity to expand Clotamin distribution into new territories
and reach millions of new potential Clotamin users. The
agreement with DS Healthcare is the first step towards achieving
that goal," stated Mackie A. Barch,
CEO of Sunpeaks Ventures. "We intend to fully utilize their
extensive technical, commercial, and regulatory expertise to build
and launch the Clotamin brand across Europe."
DS Healthcare Limited are experts in the UK/EU natural
healthcare sector and currently distribute numerous products to the
market. The company also provides consultancy services to
select healthcare businesses, including pet and equine, right
across the entire supply chain from new product development to
marketing.
About Sunpeaks Ventures, Inc.
Sunpeaks Ventures, Inc. and its wholly owned subsidiary
Healthcare Distribution Specialists, LLC ("HDS"), is a nationally
focused, value-added distributor of specialty drugs and
over-the-counter ("OTC") branded multivitamins to the healthcare
provider market. HDS also owns and markets Clotamin®, a
specialized over-the-counter multivitamin product designed
exclusively for use by patients also on Warfarin®, a popular blood
thinner that has a long list of known adverse drug and food
interactions.
For additional information, please visit
www.sunpeaksventures.com.
Contact: Financial Insights 888-248-8491 or
info@sunpeaksventures.com
Safe Harbor Statement
Information in this document constitute forward-looking
statements or statements which may be deemed or construed to be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The words
"forecast", "anticipate", "estimate", "project", "intend",
"expect", "should", "believe", and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to known and unknown risks,
uncertainties and other factors which could cause Sunpeaks
Ventures' actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and
other factors are more fully discussed in Sunpeaks Ventures'
filings with the U.S. Securities and Exchange Commission. All
forward-looking statements attributable to Sunpeaks Ventures herein
are expressly qualified in their entirety by the above-mentioned
cautionary statement. Sunpeaks Ventures disclaims any
obligation to update forward-looking statements contained in this
estimate, except as may be required by law.
SOURCE Sunpeaks Ventures, Inc.